| |
| |
|
| Insider
Information: |
Elkins David V |
| Relationship: |
Director |
| City: |
Franklin Lakes |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
196,756 |
|
|
Indirect Shares
|
216 |
|
|
| Direct
Value |
$8,859,192 |
|
|
|
Indirect Value
|
$9,733 |
|
|
| Total
Shares |
196,972 |
|
|
| Total
Value |
$8,868,925 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 5.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Becton Dickinson & Co |
BDX |
Executive VP and CFO |
2012-11-09 |
0 |
|
0 |
Premium* |
|
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
EVP, Chief Financial O... |
2024-03-10 |
194,968 |
2024-03-10 |
216 |
Premium* |
|
|
Tapestry Inc |
TPR |
Director |
2024-02-29 |
1,788 |
2024-02-29 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
52 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BDX |
Becton Dickinson & Co |
Executive VP and CFOOfficer |
• – – |
2008-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,285 |
|
- |
|
| BDX |
Becton Dickinson & Co |
Executive VP and CFO |
• – – |
2011-12-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,039) |
9,115 |
0 |
- |
|
| BDX |
Becton Dickinson & Co |
Executive VP and CFO |
• – – |
2012-11-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,513) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2019-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,947 |
24,947 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
195 |
195 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
13,908 |
13,908 |
0 |
- |
|
| CELG |
Celgene Corp |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(195) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(57,132) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
43,224 |
57,132 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,373 |
26,281 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,579 |
44,766 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2020-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,402 |
80,698 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2020-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
63,574 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2020-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,624 |
79,111 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2021-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,579 |
91,759 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
150 |
91,361 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,025 |
91,211 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2021-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,403 |
133,435 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
88,800 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,401 |
131,703 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,577 |
132,034 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,962 |
135,035 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,067 |
134,133 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2022-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
128,578 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP, Chief Financial Officer |
• – – |
2023-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
8,930 |
191,187 |
0 |
- |
|
52 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
